About Go Therapeutics
Go Therapeutics is a company based in Cambridge (United States) founded in 2013. Go Therapeutics has raised $5 million across 1 funding round from investors including Salubris Biotherapeutics. Go Therapeutics offers products and services including Discovery Platform and Super-Clean Targets. Go Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5 M (USD)
in 1 rounds
-
Latest Funding Round
$5 M (USD), Series A
Aug 08, 2017
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Go Therapeutics
Go Therapeutics offers a comprehensive portfolio of products and services, including Discovery Platform and Super-Clean Targets.
Platform to identify super-clean cancer targets for therapies
Exclusive targets for enhancing solid tumor treatments
People of Go Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Go Therapeutics
Go Therapeutics has successfully raised a total of $5M through 1 strategic funding round. The most recent funding activity was a Series A round of $5 million completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Go Therapeutics
Go Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Salubris Biotherapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibody therapeutics are developed for cancer, cardiovascular, and metabolic diseases.
|
Locked | Locked | Locked |
Investor details for Go Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Go Therapeutics
Investment portfolio details for Go Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Go Therapeutics
Detailed financials for Go Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Go Therapeutics Comparisons
Peer comparison for Go Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Go Therapeutics
Go Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Go Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Go Therapeutics
Complete news archive for Go Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Go Therapeutics
Go Therapeutics was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Go Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Go Therapeutics is a funded company, having raised a total of $5M across 1 funding round to date.
Go Therapeutics is focussed on developing tumor-specific antibodies for cancer immunotherapy. It has developed a proprietary platform to identify the sites of O-linked glycosylation on tumor-associated proteins and use the accessibility of O-glycans in the plasma membrane to develop novel hybrid epitopes that are part protein and O-glycan structure which are the targets for immunotherapeutics. Its lead candidate is in pre-clinical trials for breast cancer and other aggressive tumors.
Go Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Go Therapeutics offers Discovery Platform and Super-Clean Targets.
Go Therapeutics has 1 investor. Key investors include Salubris Biotherapeutics.